| Industry | 科学研究和技术服务业 | ||||||||||||||||||||||||
| Company Introduction | ACROBiosystems是专注于生物药开发过程的蛋白技术、产品和服务的全球化品牌，致力于提供靶向治疗药物研发过程中所需的靶点抗原及其他关键试剂和相关服务， “更特别的产品设计，更好更稳定的质量，更完备的技术帮助，更快更适当的反应”是我们希望带给客户的核心价值， 以为广大生物药开发领域客户提供一个更简便快速的药物开发过程。 北京百普赛斯生物科技股份有限公司的产品目录涵盖了从人类到其他常见物种的疾病相关的药物靶点抗原和生物标志物。我们致力于提供高质量，高批间一致性的蛋白产品， 高水平的分子互作服务（SPR&BLI）以满足药物研发领域的严格标准。 北京百普赛斯生物科技股份有限公司以更丰富的技术资源和定制服务给客户带来更多的价值，在生物药各环节提供更多的培训和交流机会，建立面向全球及每个利基市场的平台合作。 | ||||||||||||||||||||||||
| Main Business | 专业提供重组蛋白等关键生物试剂产品及技术服务。 | ||||||||||||||||||||||||
| Legal Representative | 陈宜顶 | ||||||||||||||||||||||||
| Top Executives |
|
||||||||||||||||||||||||
| Top 5 Shareholder |
|
||||||||||||||||||||||||
| Company Secretary | 林涛 | ||||||||||||||||||||||||
| Solicitors | 上海市通力律师事务所 | ||||||||||||||||||||||||
| Auditors | 容诚会计师事务所（特殊普通合伙） | ||||||||||||||||||||||||
| Tel No | 010-53395173 | ||||||||||||||||||||||||
| Fax No | 04008875666-186366 | ||||||||||||||||||||||||
| Website | www.acrobiosystems.cn | ||||||||||||||||||||||||
| IR@acrobiosystems.com | |||||||||||||||||||||||||
| Company Address |
|
||||||||||||||||||||||||
| Listing Date | 18/10/2021 | ||||||||||||||||||||||||
| Shares Capital |
|
||||||||||||||||||||||||
| EPS(RMB)* | ¥ 1.280 | ||||||||||||||||||||||||
| DPS(RMB)* | ¥ 0.900 | ||||||||||||||||||||||||
| NBV Per Share(RMB)* | ¥ 21.580 | ||||||||||||||||||||||||
| Market Capitalization(RMB) | 5.011B |
 |
Only Chinese content is avaliable |
|
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
| * | Unadjusted Data |
| Information provided by: etnet | ||
| Terms and Conditions | ||
| Risk Disclosure: |
| The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
| Disclaimer: |
| This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Chiyu Banking Corporation Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |